4DMedical Valuation
Is 4DX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4DX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 4DX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4DX's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4DX?
Key metric: As 4DX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 4DX's PB Ratio? | |
|---|---|
| PB Ratio | 2.8x |
| Book | AU$70.93m |
| Market Cap | AU$197.05m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 45.7x |
| Enterprise Value/EBITDA | -3.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 4DX's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.5x | ||
MDR MedAdvisor | 3.2x | 69.1% | AU$162.6m |
PCK PainChek | 35.5x | n/a | AU$45.8m |
ONE Oneview Healthcare | 24.7x | 43.4% | AU$209.0m |
CGS Cogstate | 2.7x | 6.6% | AU$171.8m |
4DX 4DMedical | 2.8x | 46.0% | AU$197.1m |
Price-To-Book vs Peers: 4DX is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (16.5x).
Price to Book Ratio vs Industry
How does 4DX's PB Ratio compare vs other companies in the AU Healthcare Services Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: 4DX is expensive based on its Price-To-Book Ratio (2.8x) compared to the Global Healthcare Services industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is 4DX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 4DX's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | AU$0.48 | AU$0.90 +87.5% | 16.4% | AU$1.10 | AU$0.75 | n/a | 3 |
| Nov ’25 | AU$0.54 | AU$0.90 +68.2% | 16.4% | AU$1.10 | AU$0.75 | n/a | 3 |
| Oct ’25 | AU$0.60 | AU$0.90 +50.0% | 16.4% | AU$1.10 | AU$0.75 | n/a | 3 |
| Sep ’25 | AU$0.44 | AU$0.93 +112.1% | 20.7% | AU$1.20 | AU$0.75 | n/a | 3 |
| Aug ’25 | AU$0.49 | AU$1.13 +131.3% | 4.2% | AU$1.20 | AU$1.10 | n/a | 3 |
| Jul ’25 | AU$0.55 | AU$1.13 +108.0% | 4.2% | AU$1.20 | AU$1.10 | n/a | 3 |
| Jun ’25 | AU$0.59 | AU$1.13 +92.1% | 4.2% | AU$1.20 | AU$1.10 | n/a | 3 |
| May ’25 | AU$0.62 | AU$1.13 +82.8% | 4.2% | AU$1.20 | AU$1.10 | n/a | 3 |
| Apr ’25 | AU$0.65 | AU$1.13 +74.4% | 4.2% | AU$1.20 | AU$1.10 | n/a | 3 |
| Mar ’25 | AU$0.69 | AU$1.13 +64.3% | 4.2% | AU$1.20 | AU$1.10 | n/a | 3 |
| Feb ’25 | AU$0.59 | AU$1.23 +107.3% | 10.1% | AU$1.40 | AU$1.10 | n/a | 3 |
| Jan ’25 | AU$0.71 | AU$1.25 +74.8% | 12.0% | AU$1.40 | AU$1.10 | n/a | 2 |
| Dec ’24 | AU$0.97 | AU$1.18 +21.1% | 19.1% | AU$1.40 | AU$0.95 | n/a | 2 |
| Nov ’24 | AU$0.49 | AU$0.97 +99.0% | 12.8% | AU$1.10 | AU$0.85 | AU$0.54 | 2 |
| Oct ’24 | AU$0.45 | AU$0.97 +116.7% | 12.8% | AU$1.10 | AU$0.85 | AU$0.60 | 2 |
| Sep ’24 | AU$0.65 | AU$0.97 +51.2% | 12.8% | AU$1.10 | AU$0.85 | AU$0.44 | 2 |
| Aug ’24 | AU$0.68 | AU$1.10 +61.8% | 4.5% | AU$1.15 | AU$1.05 | AU$0.49 | 2 |
| Jul ’24 | AU$0.67 | AU$1.10 +64.2% | 4.5% | AU$1.15 | AU$1.05 | AU$0.55 | 2 |
| Jun ’24 | AU$0.83 | AU$1.10 +32.5% | 4.5% | AU$1.15 | AU$1.05 | AU$0.59 | 2 |
| May ’24 | AU$0.95 | AU$1.23 +28.3% | 14.3% | AU$1.40 | AU$1.05 | AU$0.62 | 2 |
| Mar ’24 | AU$0.39 | AU$1.18 +202.6% | 18.6% | AU$1.40 | AU$0.96 | AU$0.69 | 2 |
| Feb ’24 | AU$0.43 | AU$1.33 +209.3% | 27.8% | AU$1.70 | AU$0.96 | AU$0.59 | 2 |
| Jan ’24 | AU$0.42 | AU$1.33 +216.7% | 27.8% | AU$1.70 | AU$0.96 | AU$0.71 | 2 |
| Dec ’23 | AU$0.47 | AU$1.33 +180.0% | 27.8% | AU$1.70 | AU$0.96 | AU$0.97 | 2 |
| Nov ’23 | AU$0.62 | AU$1.33 +114.5% | 27.8% | AU$1.70 | AU$0.96 | AU$0.49 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Cogstate
AU$171.8m
A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.
CGS
AU$0.99
7D
4.7%
1Y
-31.4%
SDI
AU$127.8m
Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.
SDI
AU$1.08
7D
5.4%
1Y
29.5%
Doctor Care Anywhere Group
AU$23.1m
Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.
DOC
AU$0.063
7D
-10.0%
1Y
26.0%